AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22120031 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-oriented circuit class training with motor imagery (TOCCT with MI)
Number of subjects: 30
Study 22120031 — intervention group
Group type: COMPARATOR
Intervention: Standard training program based on Bobath's neurodevelopmental technique
Number of subjects: 30
Study 19909550 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified follow up
Number of subjects: 88
Study 19909550 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative cancer relapse
Number of subjects: 88
Study 19909550 — intervention group
Group type: EXPERIMENTAL
Intervention: Locoregional relapse
Number of subjects: 88
Study 19909550 — intervention group
Group type: EXPERIMENTAL
Intervention: Distant relapse
Number of subjects: 88
Study 19909550 — intervention group
Group type: EXPERIMENTAL
Intervention: Both locoregional and distant relapse
Number of subjects: 88
Study 19909550 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage IIIA relapse
Number of subjects: 88
Study 19909550 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage IIB relapse
Number of subjects: 88
Study 19909550 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage IIA relapse
Number of subjects: 88
Study 19909550 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage IB relapse
Number of subjects: 88
Study 19909550 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean disease free interval
Number of subjects: 88
Study 19909550 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean local relapse free interval
Number of subjects: 88
Study 19909550 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean distant relapse free interval
Number of subjects: 88
Study 19909550 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse within first 12 months
Number of subjects: 88
Study 19909550 — intervention group
Group type: EXPERIMENTAL
Intervention: N stage and cancer relapse
Number of subjects: 88
Study 19909550 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant factors for survival
Number of subjects: 88
Study 19909550 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific oncological treatment of relapse
Number of subjects: 88
Study 16780811 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcosine (2 g/day) added to clozapine
Number of subjects: 20
Study 16780811 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus clozapine
Number of subjects: 20
Study 16281460 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrally-based coordinators for data collection
Number of subjects: 550
Study 16281460 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies for neuropsychological data
Number of subjects: 550
Study 16281460 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss to follow-up
Number of subjects: 550
Study 11121460 — intervention group
Group type: EXPERIMENTAL
Intervention: Social-influences, grade 3-12 intervention
Number of subjects: 8388
Study 11121460 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 8388
Study 8777117 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. diamorphine infusions
Number of subjects: 0
Study 8777117 — intervention group
Group type: COMPARATOR
Intervention: s.c. diamorphine infusions
Number of subjects: 0
Study 1705333 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular outflow tract pacing
Number of subjects: 33
Study 1705333 — intervention group
Group type: COMPARATOR
Intervention: Right ventricular apex pacing
Number of subjects: 33
Study 1705333 — intervention group
Group type: EXPERIMENTAL
Intervention: Both pacing sites
Number of subjects: 33
Study 6150408 — intervention group
Group type: EXPERIMENTAL
Intervention: Azulfidine prophylaxis
Number of subjects: 177
Study 6150408 — intervention group
Group type: COMPARATOR
Intervention: Radical operation
Number of subjects: 177
Study 6150408 — intervention group
Group type: COMPARATOR
Intervention: More restricted operation
Number of subjects: 177
Study 6150408 — intervention group
Group type: COMPARATOR
Intervention: No Azulfidine prophylaxis
Number of subjects: 177
Study 30264048 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual enhancement of occlusal morphology (MEOM)
Number of subjects: 80
Study 30264048 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MEOM)
Number of subjects: 80
Study 27022636 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive screw‐retained metal‐ceramic prosthesis in occlusion within 1 week after placement
Number of subjects: 50
Study 27022636 — intervention group
Group type: COMPARATOR
Intervention: Non‐occluding provisional acrylic reinforced prosthesis within 24 h after implant placement
Number of subjects: 50
Study 27022636 — intervention group
Group type: COMPARATOR
Intervention: Non‐occluding provisional acrylic reinforced prosthesis
Number of subjects: 50
Study 27022636 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive screw‐retained metal‐ceramic prosthesis in occlusion
Number of subjects: 50
Study 25565584 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness in Action (MIA)
Number of subjects: 124
Study 25565584 — intervention group
Group type: COMPARATOR
Intervention: Pain management psychoeducation
Number of subjects: 124
Study 25565584 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 124
Study 23426385 — intervention group
Group type: EXPERIMENTAL
Intervention: tranexamic acid (10‐mg/kg‐1 bolus and 10‐mg/kg‐1/h‐1 maintenance dose)
Number of subjects: 552
Study 23426385 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 552
Study 20573483 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous trial(s) used for sample size calculations
Number of subjects: 27
Study 20573483 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analyses cited in report discussion
Number of subjects: 27
Study 20573483 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective sample size calculations
Number of subjects: 27
Study 18649051 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 0
Study 18649051 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD+CRT
Number of subjects: 0
Study 18649051 — intervention group
Group type: EXPERIMENTAL
Intervention: ICDs alone
Number of subjects: 0
Study 15995568 — intervention group
Group type: EXPERIMENTAL
Intervention: Metotrexate
Number of subjects: 24
Study 15995568 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 24
Study 12502673 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 5 mg o.d.
Number of subjects: 16
Study 12502673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 12502673 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 16
Study 10552325 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-shift therapy (mean treatment duration 2.2 years)
Number of subjects: 44
Study 10552325 — intervention group
Group type: COMPARATOR
Intervention: Brace treatment (historical cohort, mean brace treatment 3.0 years)
Number of subjects: 44
Study 8699850 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil count measured from radial artery (RA) and coronary sinus (CS)
Number of subjects: 19
Study 8699850 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastase concentrations measured from RA and CS
Number of subjects: 19
Study 8699850 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin concentrations measured from RA and CS
Number of subjects: 19
Study 8699850 — intervention group
Group type: COMPARATOR
Intervention: Neutrophil count comparison between CS and RA
Number of subjects: 19
Study 534861 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 0
Study 534861 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 30865281 — intervention group
Group type: EXPERIMENTAL
Intervention: Asoprisnil 10 mg
Number of subjects: 907
Study 30865281 — intervention group
Group type: EXPERIMENTAL
Intervention: Asoprisnil 25 mg
Number of subjects: 907
Study 30865281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 907
Study 30865281 — intervention group
Group type: EXPERIMENTAL
Intervention: Asoprisnil (both doses)
Number of subjects: 907
Study 27749412 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluciclovine PET/CT
Number of subjects: 87
Study 27749412 — intervention group
Group type: COMPARATOR
Intervention: Conventional imaging
Number of subjects: 87
Study 25522302 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple weight control advice plus FTO feedback (FA)
Number of subjects: 1016
Study 25522302 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-risk genetic results
Number of subjects: 1016
Study 25522302 — intervention group
Group type: COMPARATOR
Intervention: Lower-risk genetic results
Number of subjects: 1016
Study 25522302 — intervention group
Group type: COMPARATOR
Intervention: Weight control advice alone (AO)
Number of subjects: 1016
Study 23478473 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-week specific strength training for the neck/shoulders
Number of subjects: 118
Study 23478473 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-week specific strength training for the neck/shoulders (per protocol adherence)
Number of subjects: 118
Study 23478473 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-week specific strength training for the neck/shoulders (medium adherence)
Number of subjects: 118
Study 23478473 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-week specific strength training for the neck/shoulders (high adherence)
Number of subjects: 118
Study 23478473 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 118
Study 22619908 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Vacuum Aspiration (MVA)
Number of subjects: 48
Study 22619908 — intervention group
Group type: COMPARATOR
Intervention: Sharp Curettage
Number of subjects: 48
Study 19746769 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene-BPO combination gel
Number of subjects: 1668
Study 19746769 — intervention group
Group type: COMPARATOR
Intervention: Adapalene monotherapy
Number of subjects: 1668
Study 19746769 — intervention group
Group type: COMPARATOR
Intervention: BPO monotherapy
Number of subjects: 1668
Study 19746769 — intervention group
Group type: COMPARATOR
Intervention: Gel vehicle
Number of subjects: 1668
Study 17990463 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiaoshui Powder
Number of subjects: 60
Study 17990463 — intervention group
Group type: COMPARATOR
Intervention: Control (conventional treatment only)
Number of subjects: 60
Study 15053839 — intervention group
Group type: EXPERIMENTAL
Intervention: Active role in decision-making
Number of subjects: 134
Study 15053839 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative role in decision-making
Number of subjects: 134
Study 15053839 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive role in decision-making
Number of subjects: 134
Study 15053839 — intervention group
Group type: EXPERIMENTAL
Intervention: Family involvement in decision-making (cancer vignette)
Number of subjects: 134
Study 15053839 — intervention group
Group type: EXPERIMENTAL
Intervention: Respecting physician's opinion
Number of subjects: 134
Study 15053839 — intervention group
Group type: EXPERIMENTAL
Intervention: Family's preference importance
Number of subjects: 134
Study 11401053 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine (HIST)
Number of subjects: 11
Study 11401053 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine (MTH)
Number of subjects: 11
Study 9553291 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated varicella vaccine combined with standard measles-mumps-rubella vaccine
Number of subjects: 118
Study 8635378 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants informed of the NC's monitoring function
Number of subjects: 231
Study 8635378 — intervention group
Group type: COMPARATOR
Intervention: Participants not informed of the NC's monitoring function
Number of subjects: 231
Study 8635378 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall compliance trends
Number of subjects: 231
Study 2404633 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised treadmill walking (1 hr/day, 3 days/wk, for 12 weeks)
Number of subjects: 19
Study 2404633 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 19
Study 7378989 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan (MEL) 0.2 mg/kg/day for five days every four weeks
Number of subjects: 427
Study 7378989 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan (MEL) plus 5-fluorouracil (FU) 15 mg/kg/day for five days every four weeks
Number of subjects: 427
Study 7378989 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan (MEL) plus 5-fluorouracil (FU) and dactinomycin (AC) 0.5 mg daily for five days every four weeks
Number of subjects: 427
Study 7378989 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoxan (CY) 7 mg/kg/day, FU 8 mg/kg/day and AC 0.5 mg/day for five days every four weeks
Number of subjects: 427
Study 30893159 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5-mL reconstitution of abobotulinumtoxinA (50 units)
Number of subjects: 60
Study 30893159 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5-mL reconstitution of abobotulinumtoxinA (50 units)
Number of subjects: 60
Study 30893159 — intervention group
Group type: EXPERIMENTAL
Intervention: Both reconstitutions
Number of subjects: 60
Study 28078503 — intervention group
Group type: EXPERIMENTAL
Intervention: HILT + GCS + EX
Number of subjects: 67
Study 28078503 — intervention group
Group type: EXPERIMENTAL
Intervention: GCS + EX
Number of subjects: 67
Study 28078503 — intervention group
Group type: COMPARATOR
Intervention: PL + EX
Number of subjects: 67
Study 24425525 — intervention group
Group type: EXPERIMENTAL
Intervention: Spin exercise
Number of subjects: 20
Study 24425525 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 20
Study 23531557 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth shielding during endovascular coil embolisation
Number of subjects: 60
Study 23531557 — intervention group
Group type: COMPARATOR
Intervention: Unshielded group during endovascular coil embolisation
Number of subjects: 60
Study 20873907 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care (N = 84)
Number of subjects: 171
Study 20873907 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (N = 85)
Number of subjects: 171
Study 19011503 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized arformoterol 15 microg BID
Number of subjects: 1429
Study 19011503 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized arformoterol 25 microg BID
Number of subjects: 1429
Study 19011503 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized arformoterol 50 microg QD
Number of subjects: 1429
Study 19011503 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol metered dose inhaler 42 microg BID
Number of subjects: 1429
Study 19011503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1429
Study 16799816 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate intake (HC) - 9.3 +/- 0 g CHO kg(‐1) day(‐1)
Number of subjects: 8
Study 16799816 — intervention group
Group type: COMPARATOR
Intervention: Low carbohydrate intake (LC) - 0.6 +/- 0.1 g CHO kg(‐1) day(‐1)
Number of subjects: 8
Study 16799816 — intervention group
Group type: COMPARATOR
Intervention: Low carbohydrate intake (LC)
Number of subjects: 8
Study 16799816 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate intake (HC)
Number of subjects: 8
Study 14719987 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy
Number of subjects: 0
Study 14719987 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by radiotherapy
Number of subjects: 0
Study 14719987 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation
Number of subjects: 0
Study 14719987 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy
Number of subjects: 0
Study 14719987 — intervention group
Group type: COMPARATOR
Intervention: Postoperative chemoradiation
Number of subjects: 0
Study 14719987 — intervention group
Group type: COMPARATOR
Intervention: Radiation doses ≥40 grays (Gy)
Number of subjects: 0
Study 14719987 — intervention group
Group type: COMPARATOR
Intervention: Postoperative irradiation
Number of subjects: 0
Study 11056095 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with periodic breathing (PB)
Number of subjects: 30
Study 11056095 — intervention group
Group type: COMPARATOR
Intervention: Patients without periodic breathing (PB)
Number of subjects: 30
Study 11056095 — intervention group
Group type: COMPARATOR
Intervention: Healthy normal subjects
Number of subjects: 30
Study 8712118 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg plus diltiazem ER 60 mg
Number of subjects: 336
Study 8712118 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg plus diltiazem ER 120 mg
Number of subjects: 336
Study 8712118 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg plus diltiazem ER 180 mg
Number of subjects: 336
Study 8712118 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg plus diltiazem ER 240 mg
Number of subjects: 336
Study 8712118 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg alone
Number of subjects: 336
Study 8712118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336
Study 1827000 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (2.5 or 5 mg twice daily)
Number of subjects: 883
Study 1827000 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (12.5 mg or 25 mg twice daily)
Number of subjects: 883
Study 1827000 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label enalapril (2.5 to 10 mg twice daily)
Number of subjects: 883
Study 6129870 — intervention group
Group type: EXPERIMENTAL
Intervention: terfenadine
Number of subjects: 312
Study 30640287 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Resistance Training (FRT)
Number of subjects: 34
Study 30640287 — intervention group
Group type: COMPARATOR
Intervention: Traditional Resistance Training (TRT)
Number of subjects: 34
Study 28378764 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief stage‐matched smoking cessation intervention (20‐minute individualized face‐to‐face counseling by trained nurses and a diabetes mellitus‐specific leaflet)
Number of subjects: 557
Study 28378764 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 557
Study 28378764 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief stage‐matched smoking cessation intervention
Number of subjects: 557
Study 24947112 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral risk-reducing mastectomy (CRRM); 242 patients (42%) underwent CRRM.
Number of subjects: 583
Study 24947112 — intervention group
Group type: COMPARATOR
Intervention: Surveillance; 341 patients (58%) remained under surveillance.
Number of subjects: 583
Study 24459240 — intervention group
Group type: EXPERIMENTAL
Intervention: Regulation of Cues (ROC) program
Number of subjects: 44
Study 24459240 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study 22710369 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-VEGF treatment
Number of subjects: 21
Study 22710369 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 21
Study 19998578 — intervention group
Group type: EXPERIMENTAL
Intervention: Otalgan ear drops containing procaine hydrochloride and phenazone
Number of subjects: 428
Study 19998578 — intervention group
Group type: EXPERIMENTAL
Intervention: Otalgan ear drops
Number of subjects: 428
Study 17303622 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamorphine 70 microg ml(‐1) and levobupivacaine (testing interval 0.004%w/v, starting at 0.044%w/v)
Number of subjects: 120
Study 17303622 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.044%w/v (fixed) and diamorphine (testing interval 7 microg ml(‐1), starting at 70 microg ml(‐1))
Number of subjects: 120
Study 17303622 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of diamorphine 69.5 microg ml(‐1) (60.5‐78.5) and levobupivacaine 0.044%w/v (0.039‐0.049)
Number of subjects: 120
Study 15449747 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of low dose morphine with bupivacaine
Number of subjects: 48
Study 15449747 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 48
Study 15449747 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 48
Study 15449747 — intervention group
Group type: COMPARATOR
Intervention: Group II (not specified intervention)
Number of subjects: 48
Study 15449747 — intervention group
Group type: COMPARATOR
Intervention: Group III (not specified intervention)
Number of subjects: 48
Study 11394734 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole-based triple therapy (LAN 30 mg BID, clarithromycin 500 mg BID, tinidazole 500 mg BID for 1 week, followed by LAN 30 mg BID for 3 weeks)
Number of subjects: 185
Study 11394734 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine bismuth citrate-based dual therapy (RBC 400 mg BID plus clarithromycin 500 mg BID for 2 weeks, followed by RBC 400 mg BID for 2 weeks)
Number of subjects: 185
Study 9715777 — intervention group
Group type: EXPERIMENTAL
Intervention: Health professionals locating the carotid pulse in less than 5 s
Number of subjects: 72
Study 9715777 — intervention group
Group type: EXPERIMENTAL
Intervention: Health professionals locating the carotid pulse in less than 10 s
Number of subjects: 72
Study 9715777 — intervention group
Group type: EXPERIMENTAL
Intervention: Influence of CPR training on pulse detection
Number of subjects: 72
Study 9715777 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck position during pulse detection
Number of subjects: 72
Study 9715777 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall performance of health professionals
Number of subjects: 72
Study 7992431 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection into the abdominal wall (SCA)
Number of subjects: 49
Study 7992431 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection into the thigh (IMT)
Number of subjects: 49
Study 7992431 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous injection into the thigh (SCT)
Number of subjects: 49
Study 2965461 — intervention group
Group type: EXPERIMENTAL
Intervention: anti‐human HBs immunoglobulin (HB Ig) and HB vaccine
Number of subjects: 29